Added to YB: 2024-04-17
Pitch date: 2024-04-16
DAWN [bullish]
Day One Biopharmaceuticals, Inc.
-43.28%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers.
Market Cap
$1.2B
Pitch Price
$14.74
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.32
P/E
-12.96
EV/Sales
6.68
Sector
Biotechnology
Category
special_situation
Show full summary:
Day One Biopharmaceuticals' Dedication to Fighting Rare Diseases
$DAWN: Breakthru therapy for pediatric low grade glioma (pLGG), no current treatment. Tovorafenib PDUFA 4/30/24, also P2 for adult glioma. Led by experienced CEO & cancer researcher co-founder. $366M cash thru 2026. Orphan drug & rare pediatric disease designation.
Read full article (2 min)